Full-Time
Data Scientist
Posted on 9/16/2025
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
No salary listed
Madrid, Spain
In Person
 Data & Analytics (1) |
|---|
- M.Sc. or PhD in Computer Science, Physics, Statistics, Mathematics or equivalent degree and experience with machine learning/data mining/artificial intelligence.
- At least 3 years of working hands-on experience as a Data Scientist.
- Proven experience to add value and insight by providing advanced analytical solutions.
- Hands-on experience with one or several fields of data mining, machine learning, statistics and prediction, image processing, natural language processing, deep learning, and other ML algorithms.
- Good knowledge of regulatory aspects regarding the validation of AI-based solutions in healthcare production processes and digital products.
- Experience with data and statistical languages/tools such as SQL, R, Python, etc.
- Data storytelling skills and using visualisation tools to communicate data and results with a non-technical audience.
- International, goal oriented mindset with can do attitude.
- Fluency in written and spoken English.
- Be accountable for the development and implementation of Data Science products.
- Support proactive identification of the most relevant analytical use cases in collaboration with the key stakeholders.
- Support prioritization efforts, understand feasibility and business impact, take smart risks to make informed decisions in a fast-paced, evolving environment to deliver patient benefits faster.
- Collaborate within global agile teams in the Roche Informatics business and foundational domains to develop products that provide the highest value to both Roche Pharma and Diagnostics business stakeholders.
- Provide methodical and implementation guidance as well as hands-on support around analytical use cases.
- Communicate findings and market the value of use cases to key stakeholders.
- Contribute to positioning data science as a key competency within the enterprise.
- Continuously look for opportunities to broaden knowledge, capabilities and skill set to enable talent to flow into different specialties.
- Be a role model for knowledge sharing within the DnA chapter.
- Act as a coach, mentor, or buddy to help colleagues grow and develop.
- Experience in the pharmaceutical/biotech industry is preferred.
- Experience in working with cloud technologies and data science workbenches is preferred.
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Simplify's Take
What believers are saying
- PathAI can strengthen AI pathology workflows and biomarker discovery.
- Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
- Nurix collaboration deepens Roche's reach into protein degradation and hematology.
What critics are saying
- Swiss franc strength keeps distorting reported growth and investor perception.
- Patent expirations on older medicines force rapid replacement from newer assets.
- CT-388 must beat Novo Nordisk and Eli Lilly to matter.
What makes Roche unique
- Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
- Founded in Basel in 1896, Roche built scale through branded medicines.
- Genentech integration made Roche the world's largest biotechnology company.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Roche who can refer or advise you
Benefits
Performance Bonus
Company News
SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.
Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.
Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.
Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.
Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.